Literature DB >> 2779612

Comparison of ketoconazole suspension and nystatin in the treatment of newborns and infants with oral candidosis.

J M Boon, H N Lafeber, A H Mannetje, A H van Olphen, H L Smeets, J Toorman, G J van der Vlist.   

Abstract

Ketoconazole suspension (20 mg per ml) was compared with nystatin (100,000 units per ml) in the treatment of oral candidosis in newborns and infants. In all patients Candida infection was proven by culture. Twenty patients were treated with ketoconazole and 15 patients with nystatin. Treatment was discontinued 2 days after clinical cure, or after 3 weeks. The investigator assessed the severity of the thrush and accompanying symptoms at the start of the study and at weekly controls. After one week all 20 patients on ketoconazole (100%) and 8 (53%) patients on nystatin were cured clinically. At the end of the treatment 12 patients on nystatin (80%) were cured. Clinical cure was confirmed by negative culture in 94% of the patients on ketoconazole and in 73% of the patients on nystatin. No side-effects were observed in the patients on ketoconazole. Only in the case of one patient on nystatin, was vomiting observed. This study shows that ketoconazole cures thrush faster and more effectively than nystatin.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2779612     DOI: 10.1111/j.1439-0507.1989.tb02250.x

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  4 in total

Review 1.  Mouthwashes in the treatment of oral disease.

Authors:  D J Zegarelli
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

2.  Antifungal agents for common paediatric infections.

Authors: 
Journal:  Paediatr Child Health       Date:  2007-12       Impact factor: 2.253

3.  Antifungal agents for common paediatric infections.

Authors: 
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-01       Impact factor: 2.471

4.  Antifungal agents for common paediatric infections.

Authors: 
Journal:  Paediatr Child Health       Date:  2000-11       Impact factor: 2.253

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.